IBMS BoneKEy | Clinical Cases
Response to Teriparatide in a patient with bisphosphonate-induced atypical femur fracture
Sahana Shetty
Nitin Kapoor
Nihal Thomas
Thomas V Paul
DOI:10.1038/bonekey.2014.54
Abstract
Bisphosphonates are the first-line and commonly prescribed drugs for the treatment of osteoporosis. They act by decreasing bone resorption, hence altering bone remodeling, which may lead to a low bone turnover state. Atypical femur fracture is one of the rare complications seen following prolonged use of bisphosphonates. We report a 1-year follow-up of our previously published case of atypical femur fracture and its response to Teriparatide, and a brief review of literature.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.